Following tumor establishment, mice were divided into three groups: a treatment group receiving anti-HER2/neu TCR-engineered T cells (HER2/neu), a control group receiving non-transduced T cells (LV-neg), and an untreated control group (Control). This evidence concerns the gene ERBB2 and neoplasm.